Didn't kite do a few partnership deals where they didn't hold 100% of the IP. Wow, and they still were able to do a non-breadcrumb deal. I would take 1/2 that deal right now.
Gilead made it's immuno-oncology move for Kite's CAR-T, paying $11.9 billion. GILD needs to make another move for the necessary safety augmentation that CAR-T requires for efficacy AND safety.
What's left in the tank?
Novartis already has it's CAR-T. The MSK Wolchok lab has demonstrated that anti-PS provides that needed safety when used in combination with CAR-T therapy. Will Novartis now make a move for Peregrine's anti-PS??
Between Gilead and Novartis, which company has the deeper pockets for an acquisition of the PPHM anti-PS IP? Obviously Novartis. Both companies have the need for CAR-T safety.
Market Data 
Markets 
AI
